Development of shellfish allergy after exposure to dual immune checkpoint blockade. (9th February 2018)

• Record Type: Journal Article
• Authors: Brown, Zachary J; Heinrich, Bernd; Greten, Tim F
• Is Part Of: Hepatic oncology. Volume 5:Number 1(2018)
• Publication Date: 2018-02-09
• Subjects: allergy -- checkpoint inhibitors -- durvalumab -- hepatocellular carcinoma -- immunotherapy -- tremelimumab; Liver -- Cancer -- Periodicals; 616.99436005
• DOI: 10.2217/hep-2017-0021
• Languages: English
• ISSNs: 2045-0923

Abstract

Hepatocellular carcinoma (HCC) is a major health problem worldwide with limited systemic therapies available. Immunotherapy is a fast-moving field that is quickly evolving as a treatment for HCC with three recent clinical trials published treating HCC with immune checkpoint inhibitors with promising results. Checkpoint inhibition may lead to a unique adverse event profile with the potential to cause immune-related adverse events by unbalancing the immune system. Here, we report a case of a 61-year-old male with advanced HCC who developed a shellfish allergy after completing three cycles of combination of tremelimumab and durvalumab therapy.